Focus on the potential role of ficlatuzumab in the treatment of non-small cell lung cancer

cus on the potential role of ficlatuzumab in the treatment of non-small cell lung cancer Review (454) Total Article Views Authors: D'Arcangelo M, Cappuzzo F Published Date March 2013 Volume 2013:7 Pages 61 - 68 DOI: http://dx.doi.org/10.2147/BTT.S28908 Received: 08 January 2013 Accepted: 25 January 2013 Published: 04 March 2013 Manolo D’Arcangelo,1,2 Federico Cappuzzo2 1Cancer Center, University of Colorado, Aurora (CO), USA; 2Department of Oncology, Istituto Toscano Tumori, Ospedale Civile, Livorno, Italy Abstract: Lung cancer treatment has rapidly changed in the last few years thanks to novel insights into cancer biology. Several biomarkers and signaling pathways have been recognized as conceivable targets for treatment, and among them is the mesenchymal–epithelial transition/hepatocyte growth factor (c-MET/HGF) axis. Alterations in the c-MET gene and aberrations of MET and HGF expression impact on lung cancer prognosis and are involved in resistance to epidermal growth factor receptor (EGFR) inhibitors in non-small cell lung cancer (NSCLC) patients harboring activating EGFR mutations. Several anti-MET and anti-HGF strategies are currently under investigation, including monoclonal antibodies. Ficlatuzumab is a monoclonal antibody directed against HGF that is currently under investigation in NSCLC. The aim of the present review is to critically review available data on HGF and ficlatuzumab in NSCLC.